OXON’s COVID-19 Research Programme
OXON collaborates with academics and clinicians in not-for-profit international programme to evaluate non-randomised comparative studies of treatments for COVID-19 and prognostic factors
OXON collaborates with academics and clinicians in not-for-profit international programme to evaluate non-randomised comparative studies of treatments for COVID-19 and prognostic factors
OXON will be speaking and exhibiting at World Drug Safety Congress 2019 in Amsterdam on September 10-11, 2019.
OXON will be speaking and exhibiting at World Drug Safety Congress 2019 in Amsterdam on September 10-11, 2019.
OXON will be supporting the International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) in Philadelphia on August 24-28, 2019.
22nd – 23rd May 2019,
Holiday Inn London Kensington Hotel, London UK
Nawab Qizilbash, Head of OXON, will be speaking about PASS Studies.
Nawab Qizilbash will speak and show a selection of practical examples and case studies under the title “Trials with observational designs”
OXON will present a review and discuss lessons learned from risk minimisation evaluation studies at the EFPIA PV Expert Group
OXON will be presenting at the 20th Annual European Congress of ISPOR:
two poster presentations focused on Clinical Outcomes Studies
Head of OXON, Dr Nawab Qizilbash will participate
in EMA/DIA Information Day on
Measuring the Impact on Pharmacovigilance Activities.
OXON will be attending the ISPE Mid-Year Meeting with the theme “Ensuring Opportunities Become Reality”, held on April 1 – 4, 2017 at The Royal College of Physicians, London, United Kingdom.